About Jacques P. Tremblay (Ph.D.), 2013 Canadian Ataxia Conference speaker:

Dr. Jacques P. Tremblay will be presenting at the Canadian Ataxia Conference 2013 on Saturday October 12th at 2:30pm. His presentation will take place in the Stevenson and Hunt Room. Dr. Tremblay will also attend the Claude St-Jean tribute banquet as a Guest of Honour.

Dr. Tremblay completed a B.A. at college Ste Marie in 1967 and a B.Sc. in Honours Biochemistry at Mc Gill University in 1970. He obtained in 1974 a Ph.D. in Neuroscience from the University of California in San Diego (UCSD). He is a professor at Laval University since 1976 and a full professor since 1985. He was the chairman of the department of Anatomy from 1987 to 1997.

Dr. Tremblay has published 183 articles in peer reviewed journals and presented 304 communications in congress. He has presented 75 invited conferences in international congress. The aim of Dr. Tremblay laboratory is to develop a treatment for recessive muscular dystrophies, particularly Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy and Hereditary Inclusion Body Myopathies (HIBM) based on the transplantation of allogeneic normal or autologous genetically corrected muscle precursor cells (myoblasts).

The research conducted by Dr. Tremblay team has permitted excellent transplantation results in animal models. In dystrophic mice, the transplantation of myoblasts has restored the expression of dystrophin in 95% of the muscle fibers. More than 30,000 muscle fibers expressed a reporter gene following the transplantation of genetically modified myoblasts throughout the biceps of monkeys immunosuppressed with Tacrolimus (Prograft). This success permitted to this team to obtain the permission from Health Canada to do a phase I clinical trial of myoblast transplantation to DMD patients. Dystrophin expression was observed in the muscle fibers of eight of the nine patients who received myoblast transplantation during this clinical trial. His team has recently obtained the permission to undertake a follow-up clinical trial to verify whether the transplantation of normal myoblasts throughout one arm muscle can increase the strength of that muscle.

"Development of a potential therapy for Friedreich ataxia" is a research project is directed by Dr. Jacques P. Tremblay, Ph.D., professor in the Department of Molecular Medicine of Laval University in Quebec and main investigator at the Research Centre of Quebec City (CHUL). Duration of the project is two (2) years and its cost is $240,000. This project is totally funded by CAFA – Claude St-Jean Foundation (http://www.lacaf.org).

To learn more about Dr. Jacques P.Tremblay visit his [Laval University website] or watch his [Conference about the research project on Friedreich Ataxia] video.

Sources and Links: http://jptremblaylab.crchul.ulaval.ca, photo of Jacques P. Tremblay highlighted is from the webpage http://jptremblaylab.crchul.ulaval.ca